

Preclinical work

Clinical evidence SeQuent® SCB
Preclinical work & randomized
controlled trials


Preclinical work

Sirolimus + BHT (Butylated Hydroxy Toluol): Persistence in the vessel wall

- Porcine overstretch model
- Persistence of sirolimus in the vessel wall: **40% to 50% of the transferred drug** until 1 month (SeQuent® SCB)
- Similar efficacy to reduce intimal hyperplasia as compared to the SeQuent® Please paclitaxel-coated balloon ^[1]


Sirolimus + BHT

- Controlled release of Sirolimus
- Creation of the desired crystalline sirolimus modification ^[1]



Representative histological examples. Top left, Uncoated control; top right, AS. Bottom, from left to right: Vb 4, Vb 7, SeQuent® Please. AS indicates amorphous sirolimus coating; and Vb, crystalline sirolimus coating.

Drug release and drug persistence in the vessel wall



Drug transfer (Tissue concentration)

After 28 days: 40 to 50% of the initial transferred sirolimus dose are still within the arterial wall. [1]

[1] Clever et al. Circ Cardiovasc Interv. 2016 Apr;9(4):e003543.